Skip to content

Optimizing NIPPV Use for Patients With ALS

Effectiveness Trial of Detailed NIPPV Feedback to Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01035476
Enrollment
31
Registered
2009-12-18
Start date
2009-12-31
Completion date
2011-12-31
Last updated
2016-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALS

Keywords

ALS, nasal ventilation, data card recording

Brief summary

This research will examine the utility of the data card recording capacity of nasal ventilation devices (NIPPV) in people with ALS to optimize use.

Detailed description

The data card records critical features of NIPPV acceptance (hours and timing of use) and adherence (apnea/hypopnea index, mask leak, minute ventilation); but to date data card monitoring has not yet been incorporated fully into ALS clinic practice. We will limit our focus to patients who meet Medicare-reimbursement criteria or AAN-recommended practice parameters for initiating NIPPV. The larger question guiding this research is whether data card monitoring and communication of these results to clinicians and patient families promotes optimal use of NIPPV. We define optimal use as (i) high acceptance, as indicated by daily night time use greater than 4 hours, and (ii) high adherence, as indicated by apnea/hypopnea index, mask leak, and minute ventilation. We will test whether timely reporting of acceptance and adherence values to patients and clinicians increases the likelihood of (i) changes in orofacial masks and settings on devices and continued use of devices, and (ii) positive patient mood and sleep quality and lower caregiver burden over follow-up.

Interventions

BEHAVIORALData Card Report

Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.

Sponsors

ALS Association
CollaboratorOTHER
University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Definite or probable ALS * Medicare or AAN criteria for initiating NIPPV * Community resident * English speaker

Exclusion criteria

* Unable to give informed consent * Other pulmonary or cardiac conditions that complicate use of NIPPV * Report from physician that participation would be harmful

Design outcomes

Primary

MeasureTime frame
Length of time on NIPPV6 months

Secondary

MeasureTime frame
Patient sleep quality, mood, fatigue6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026